RU2012104795A - METHOD FOR PRODUCING 1- (2-HALOGENOBIPHENYL-4-IL)-CYCLOPROPANOCARBOXYLIC ACID DERIVATIVES - Google Patents

METHOD FOR PRODUCING 1- (2-HALOGENOBIPHENYL-4-IL)-CYCLOPROPANOCARBOXYLIC ACID DERIVATIVES Download PDF

Info

Publication number
RU2012104795A
RU2012104795A RU2012104795/04A RU2012104795A RU2012104795A RU 2012104795 A RU2012104795 A RU 2012104795A RU 2012104795/04 A RU2012104795/04 A RU 2012104795/04A RU 2012104795 A RU2012104795 A RU 2012104795A RU 2012104795 A RU2012104795 A RU 2012104795A
Authority
RU
Russia
Prior art keywords
formula
compound
palladium
steps
compounds
Prior art date
Application number
RU2012104795/04A
Other languages
Russian (ru)
Other versions
RU2540076C2 (en
Inventor
Фаусто Пиветти
Мариа Джоя ФОРНАРЕТТО
Марко Ре
Original Assignee
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. filed Critical КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.
Publication of RU2012104795A publication Critical patent/RU2012104795A/en
Application granted granted Critical
Publication of RU2540076C2 publication Critical patent/RU2540076C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/54—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
    • B01J23/56—Platinum group metals
    • B01J23/58—Platinum group metals with alkali- or alkaline earth metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/14—Preparation of carboxylic acid nitriles by reaction of cyanides with halogen-containing compounds with replacement of halogen atoms by cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Materials Engineering (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)

Abstract

1. Способ получения соединения формулы (IA)где R представляет собой одну или более групп, независимо выбранных из атомов галогенов;и его фармацевтически приемлемых солей,включающий следующие стадии:(1) взаимодействие соединения формулы (IV)где X' выбран из хлора, брома, йода и трифлатной группы (CFSO), с 1,2-дибромэтаном с образованием соединения формулы (V)(2) связывание соединения формулы (V) с соединением формулы (VI)где R такой, как определено выше, с образованием соединения формулы (VII);(3) гидролиз соединения формулы (VII) с получением соединения формулы (IA).2. Способ по п.1, где X' представляет собой бромид.3. Способ по п.1, дополнительно включающий стадии выделения и кристаллизации соединения формулы (IA).4. Способ по п.1, где стадию (2) проводят в присутствии палладиевого катализатора, выбранного из тетракис(трифенилфосфин)палладия, палладия на активированном угле, палладия на оксиде алюминия и смеси Pd(ОСОСН)и трифенилфосфина (PPh).5. Способ по п.4, где палладиевый катализатор представляет собой смесь 1:2 масс./масс. Pd(OCOCH)и PPh.6. Способ по п.1, дополнительно включающий следующие стадии:(1) подвергание соединения формулы (II)где X' такой, как определено выше, радикальному бромированию с образованием соединения формулы (III);(2) превращение соединения формулы (III) в соответствующее нитрильное производное формулы (IV).7. Способ по п.6, где стадию бромирования проводят N-бромсукцинимидом в присутствии каталитического количества бензоилпероксида с использованием ацетонитрила качестве растворителя.8. Способ по п.1, где атом галогена представляет собой атом хлора.9. Способ по п.7, где соединение формулы (1А) представляет собой 1-(3',4'-дихлор-2-фтор[1,1'-бифенил]-4-ил)1. A method of obtaining a compound of formula (IA) where R represents one or more groups independently selected from halogen atoms and its pharmaceutically acceptable salts, comprising the following steps: (1) reacting a compound of formula (IV) where X 'is selected from chlorine, bromine, iodine and triflate group (CFSO), with 1,2-dibromoethane to form a compound of formula (V) (2) linking a compound of formula (V) to a compound of formula (VI) where R is as defined above to form a compound of formula (VII); (3) hydrolysis of a compound of formula (VII) to obtain a compound of formula (IA) .2. The method of claim 1, wherein X 'is bromide. 3. The method of claim 1, further comprising the steps of isolating and crystallizing the compound of formula (IA). The method according to claim 1, wherein step (2) is carried out in the presence of a palladium catalyst selected from tetrakis (triphenylphosphine) palladium, palladium on activated carbon, palladium on alumina and a mixture of Pd (OCOCH) and triphenylphosphine (PPh). The method according to claim 4, where the palladium catalyst is a mixture of 1: 2 wt./mass. Pd (OCOCH) and PPh. 6. The method according to claim 1, further comprising the following steps: (1) subjecting the compound of formula (II) to wherein X 'is as defined above, radical bromination to form a compound of formula (III); (2) converting the compound of formula (III) to the corresponding nitrile derivative of the formula (IV) .7. The method of claim 6, wherein the bromination step is carried out with N-bromosuccinimide in the presence of a catalytic amount of benzoyl peroxide using acetonitrile as a solvent. The method of claim 1, wherein the halogen atom is a chlorine atom. The method according to claim 7, where the compound of formula (1A) is 1- (3 ', 4'-dichloro-2-fluoro [1,1'-biphenyl] -4-yl)

Claims (10)

1. Способ получения соединения формулы (IA)1. The method of obtaining the compounds of formula (IA)
Figure 00000001
Figure 00000001
 где R представляет собой одну или более групп, независимо выбранных из атомов галогенов;where R represents one or more groups independently selected from halogen atoms; и его фармацевтически приемлемых солей,and its pharmaceutically acceptable salts, включающий следующие стадии:comprising the following steps: (1) взаимодействие соединения формулы (IV)(1) the interaction of the compounds of formula (IV)
Figure 00000002
Figure 00000002
 где X' выбран из хлора, брома, йода и трифлатной группы (CF3SO3), с 1,2-дибромэтаном с образованием соединения формулы (V)where X 'is selected from chlorine, bromine, iodine and a triflate group (CF 3 SO 3 ), with 1,2-dibromoethane to form a compound of formula (V)
Figure 00000003
Figure 00000003
 (2) связывание соединения формулы (V) с соединением формулы (VI)(2) binding of a compound of formula (V) to a compound of formula (VI)
Figure 00000004
Figure 00000004
 где R такой, как определено выше, с образованием соединения формулы (VII);where R is as defined above, with the formation of the compounds of formula (VII);
Figure 00000005
Figure 00000005
 (3) гидролиз соединения формулы (VII) с получением соединения формулы (IA).(3) hydrolysis of a compound of formula (VII) to obtain a compound of formula (IA). 2. Способ по п.1, где X' представляет собой бромид.2. The method according to claim 1, where X 'is a bromide. 3. Способ по п.1, дополнительно включающий стадии выделения и кристаллизации соединения формулы (IA).3. The method of claim 1, further comprising the steps of isolating and crystallizing the compound of formula (IA). 4. Способ по п.1, где стадию (2) проводят в присутствии палладиевого катализатора, выбранного из тетракис(трифенилфосфин)палладия, палладия на активированном угле, палладия на оксиде алюминия и смеси Pd(ОСОСН3)2 и трифенилфосфина (PPh3).4. The method according to claim 1, where stage (2) is carried out in the presence of a palladium catalyst selected from tetrakis (triphenylphosphine) palladium, palladium on activated carbon, palladium on alumina and a mixture of Pd (OCOCH 3 ) 2 and triphenylphosphine (PPh 3 ) . 5. Способ по п.4, где палладиевый катализатор представляет собой смесь 1:2 масс./масс. Pd(OCOCH3)2 и PPh3.5. The method according to claim 4, where the palladium catalyst is a mixture of 1: 2 wt./mass. Pd (OCOCH 3 ) 2 and PPh 3 . 6. Способ по п.1, дополнительно включающий следующие стадии:6. The method according to claim 1, further comprising the following steps: (1) подвергание соединения формулы (II)(1) exposure to a compound of formula (II)
Figure 00000006
Figure 00000006
 где X' такой, как определено выше, радикальному бромированию с образованием соединения формулы (III);where X 'is as defined above, radical bromination with the formation of the compounds of formula (III);
Figure 00000007
Figure 00000007
 (2) превращение соединения формулы (III) в соответствующее нитрильное производное формулы (IV).(2) the conversion of a compound of formula (III) into the corresponding nitrile derivative of formula (IV). 7. Способ по п.6, где стадию бромирования проводят N-бромсукцинимидом в присутствии каталитического количества бензоилпероксида с использованием ацетонитрила качестве растворителя.7. The method according to claim 6, where the stage of bromination is carried out with N-bromosuccinimide in the presence of a catalytic amount of benzoyl peroxide using acetonitrile as a solvent. 8. Способ по п.1, где атом галогена представляет собой атом хлора.8. The method according to claim 1, where the halogen atom is a chlorine atom. 9. Способ по п.7, где соединение формулы (1А) представляет собой 1-(3',4'-дихлор-2-фтор[1,1'-бифенил]-4-ил)-циклопропанкарбоновую кислоту.9. The method according to claim 7, where the compound of formula (1A) is 1- (3 ', 4'-dichloro-2-fluoro [1,1'-biphenyl] -4-yl) -cyclopropanecarboxylic acid. 10. Способ получения фармацевтической композиции, включающий стадии (1)-(3) из п.1 и дополнительную стадию, включающую смешивание с одним или более фармацевтически приемлемыми эксципиентами. 10. A method of obtaining a pharmaceutical composition comprising the steps (1) to (3) of claim 1 and an additional step comprising admixing with one or more pharmaceutically acceptable excipients.
RU2012104795/04A 2009-08-04 2010-07-22 Method for preparing 1-(2-halogenobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives RU2540076C2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167206.3 2009-08-04
EP09167206 2009-08-04
PCT/EP2010/004481 WO2011015287A2 (en) 2009-08-04 2010-07-22 Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Publications (2)

Publication Number Publication Date
RU2012104795A true RU2012104795A (en) 2013-09-10
RU2540076C2 RU2540076C2 (en) 2015-01-27

Family

ID=41479261

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012104795/04A RU2540076C2 (en) 2009-08-04 2010-07-22 Method for preparing 1-(2-halogenobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives

Country Status (22)

Country Link
US (1) US9056818B2 (en)
EP (1) EP2462098B1 (en)
JP (2) JP5996428B2 (en)
KR (1) KR101737653B1 (en)
CN (1) CN102596879B (en)
AU (1) AU2010281069B2 (en)
BR (1) BR112012002500A2 (en)
CA (1) CA2769960C (en)
DK (1) DK2462098T3 (en)
ES (1) ES2437163T3 (en)
HK (1) HK1168588A1 (en)
HR (1) HRP20140032T1 (en)
IL (1) IL217886A (en)
MX (1) MX2012001411A (en)
MY (1) MY152980A (en)
PT (1) PT2462098E (en)
RU (1) RU2540076C2 (en)
SG (1) SG178239A1 (en)
SI (1) SI2462098T1 (en)
UA (1) UA106619C2 (en)
WO (1) WO2011015287A2 (en)
ZA (1) ZA201200821B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133322A1 (en) * 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
SG178239A1 (en) * 2009-08-04 2012-03-29 Chiesi Farma Spa Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
WO2011120778A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Novel polymorphs and salts
US8975438B2 (en) * 2011-07-13 2015-03-10 Hoffmann-La Roche Inc. Process for the preparation of cyclohexanecarboxylic acid derivatives
US9592210B2 (en) 2011-12-22 2017-03-14 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment
BR112014023670A8 (en) 2012-04-04 2017-07-25 Chiesi Farm Spa COMPOUND, PHARMACEUTICAL COMPOSITION AND THE SWITCH OF A COMPOUND
EP2818460A1 (en) 2013-06-24 2014-12-31 ZaCh System S.p.A. Cyclopropanation of substituted phenylacetonitriles or phenyl acetates
EP3013786B1 (en) * 2013-06-24 2018-04-04 Chiesi Farmaceutici S.p.A. Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
WO2023034184A1 (en) 2021-08-31 2023-03-09 Cerespir Incorporated Co-crystals

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030311A1 (en) * 2003-02-21 2004-08-22 Chiesi Farma Spa 2-FENYL-2-DIALKYL-ACETIC ACIDS FOR THE TREATMENT OF ALZHEIMER DISEASE.
KR101152448B1 (en) * 2003-02-21 2012-07-02 키에시 파르마슈티시 엣스. 피. 에이. Preparation method of 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
JP2005047842A (en) * 2003-07-31 2005-02-24 Mitsubishi Chemicals Corp Method for producing organic compound
EP1650183A1 (en) * 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
AU2006257670A1 (en) * 2005-06-14 2006-12-21 Merck Frosst Canada Ltd Reversible inhibitors of monoamine oxidase A and B
JP5070067B2 (en) * 2007-01-15 2012-11-07 参天製薬株式会社 Novel indole derivatives having IκB kinase β inhibitory activity
EP2133322A1 (en) 2008-06-11 2009-12-16 CHIESI FARMACEUTICI S.p.A. Process of preparing derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
SG178239A1 (en) * 2009-08-04 2012-03-29 Chiesi Farma Spa Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid

Also Published As

Publication number Publication date
IL217886A (en) 2014-11-30
AU2010281069B2 (en) 2015-09-10
ES2437163T3 (en) 2014-01-09
MX2012001411A (en) 2012-03-29
BR112012002500A2 (en) 2018-03-13
KR101737653B1 (en) 2017-05-18
JP2015131824A (en) 2015-07-23
CA2769960A1 (en) 2011-02-10
RU2540076C2 (en) 2015-01-27
CN102596879B (en) 2015-01-28
KR20120050977A (en) 2012-05-21
WO2011015287A2 (en) 2011-02-10
EP2462098A2 (en) 2012-06-13
UA106619C2 (en) 2014-09-25
CN102596879A (en) 2012-07-18
EP2462098B1 (en) 2013-10-23
PT2462098E (en) 2013-12-04
CA2769960C (en) 2017-04-18
HK1168588A1 (en) 2013-01-04
US9056818B2 (en) 2015-06-16
ZA201200821B (en) 2013-05-29
MY152980A (en) 2014-12-15
JP6001112B2 (en) 2016-10-05
WO2011015287A3 (en) 2011-03-31
JP2013501010A (en) 2013-01-10
IL217886A0 (en) 2012-03-29
SI2462098T1 (en) 2014-01-31
HRP20140032T1 (en) 2014-02-14
SG178239A1 (en) 2012-03-29
AU2010281069A1 (en) 2012-02-23
JP5996428B2 (en) 2016-09-21
DK2462098T3 (en) 2013-11-25
US20110039934A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
RU2012104795A (en) METHOD FOR PRODUCING 1- (2-HALOGENOBIPHENYL-4-IL)-CYCLOPROPANOCARBOXYLIC ACID DERIVATIVES
RU2010146299A (en) METHOD FOR PRODUCING 1- (2-HALOGENOBIPHENYL-4-IL)-CYCLOPROPANOCARBOXYLIC ACID DERIVATIVES
JP2013249315A5 (en)
JP2012503016A5 (en)
CN103497180A (en) Synthetic method of 4-(2,2-difluoro-1,3-benzodioxole-4-yl)pyrrole-3-nitrile
JP2004189841A5 (en)
JP2013521225A (en) Rosuvastatin calcium intermediate product and preparation method thereof
CN103420908B (en) The preparation method of montelukast chiral intermediate
CN105418612B (en) Preparation method of doxofylline
JP2006117593A (en) New fluorescent compound and method for producing the same
JP2005516905A5 (en)
CN104193664A (en) Synthesis method of imrecoxib
CN1182113C (en) 2,5-cis-bisubstituted pyrrolidine derivative and its preparing process and usage
CN1557796A (en) Process for synthesizing sex pheromone of pine caterpillar
CN102199154A (en) Novel synthesis method for pyrrole derivatives
JP2011140474A (en) Method for producing difluorocyclopropane compound
CN105801577B (en) A kind of methyl substituted pyrroles of polyfluoro [3,2 c] and the preparation method of quinolines
JPWO2011111762A1 (en) Method for producing diaryl derivative, novel binaphthyl derivative, method for producing arene derivative, and novel arene derivative
JP5818278B2 (en) Improved synthesis of peretinoin
KR101303916B1 (en) Potassium styrenyl trifluoroborate derivatives and method for producing the same
CN110256274B (en) Method for preparing N-methyl-N-phenyl-2, 3-dibromo-3-substituted phenylpropionamide compound
CN105693685A (en) Preparation technique of olopatadine hydrochloride
CA2915773A1 (en) Improved process for the preparation of derivatives of 1-(2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid
JP5298678B2 (en) (Arylloyl or heteroaryloyl) methylpentafluorosulfanylbenzene compound production method
JP4953754B2 (en) Halohydrin compounds